[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Wisconsin, Madison\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":570},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,172,0,25,[9,47,70,93,115,139,161,181,207,227,250,270,294,312,332,358,380,406,425,444,465,487,516,532,549],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100649002","pcos-and-brain-health-100649002",false,"NCT07727512","PCOS and Brain Health","Functional and Structural Impacts of Polycystic Ovary Syndrome (PCOS) on Brain Health","Inclusion Criteria (Participants with PCOS):\n\n* Rotterdam criteria demonstrating two out of the three criteria. These are:\n\n  1. Presence of clinical hyperandrogenism or biochemical hyperandrogenism\n  2. A history of irregular menstrual cycles\n  3. Presence of polycystic ovarian morphology on ultrasound\n\nInclusion Criteria (Healthy Controls):\n\n* Regular menstrual cycles (not meeting criteria for irregular cycles above)\n* No diagnosis of PCOS\n* Controls may have isolated hirsutism or polycystic ovaries on ultrasound as long as they do not meet Rotterdam criteria for PCOS\n\nExclusion Criteria:\n\n* Current pregnancy\n* Preexisting diagnosis of type 1 diabetes\n* Severe obesity (body mass index (BMI) greater than 45kg\u002Fm2)\n* Preexisting diagnosis of hypertension requiring antihypertensive medication or blood pressure of greater than 160\u002F100 on two separate occasions during clinical care\n* History of neurologic disease or stroke\n* History of myocardial infarction or deep venous thrombosis\n* Endometriosis confirmed by prior laparoscopy\n* Autoimmune conditions including lupus, multiple sclerosis, and active malignancy\n* Immuno-modulating medications\n* Conditions incompatible with MRI scanning, including but not limited to\n\n  * Certain implanted metal devices or foreign bodies\n  * Severe claustrophobia\n* Post-menopausal\n* Participants will be excluded if they have taken hormonal contraception or fertility medication in the last month",true,"FEMALE","18 Years","45 Years",{"count":22,"type":23},45,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to determine how polycystic ovary syndrome (PCOS) impacts overall brain health, such as cerebral blood flow (CBF), brain structure and connectivity, and cognitive performance. 45 reproductive aged (18-45 years) individuals with ovaries, with and without PCOS, will be enrolled to complete brain structure and CBF scans via magnetic resonance imaging (MRI) over 2 testing visits and can expect to be on study for approximately 5 hours over a 1 to 3 month period.",[27],"PCOS",[29,30,31,32,33],"brain health","cerebral blood flow","polycystic ovarian syndrome","brain structure","cognition","RECRUITING","2026-08-19",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":38},"2026-08-07",{"date":42,"type":23},"2028-08",{"name":44,"class":45},"University of Wisconsin, Madison","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100608139","phase-1-y-nm600-in-patients-receiving-anti-pd-1-or-anti-pd-l1-for-metastatic-cancer-100608139","NCT07197671","Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer","Phase 1 Study of Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 Therapy for Metastatic Cancer","Inclusion Criteria:\n\n1. Participant must be informed of the investigational nature of the study and must be able to sign a written informed consent.\n2. Participants with histologically or cytologically confirmed squamous cell carcinoma thought to originate from the head and neck region (HNC).\n3. Participants must have metastatic solid malignancy, non-hematological.\n4. Participants must be under treatment with one of the following FDA-approved standard-of-care anti-PD-1 or anti-PD-L1 therapies: Pembrolizumab (Keytruda; anti-PD-1 antibody), Nivolumab (Opdivo; anti-PD-1 antibody), Atezolizumab (Tecentriq, anti-PD-L1 antibody), Avelumab (Bavencio; anti-PD-L1 antibody), Durvalumab (Imfinzi; anti-PD-L1 antibody), Cemiplimab (Libtayo; anti-PD-1 antibody), Dostarlimab (Jemperli; anti-PD-1 antibody). Participants may be on additional FDA-approved immunotherapy treatments including anti-CTLA4 therapies or anti-LAG-3 therapies in addition to the anti-PD-1 or anti-PD-L1 backbone therapy. The specific additional therapies allowed are: Ipilimumab (Yervoy; anti-CTLA4 antibody), Tremelimumab (Imjudo; anti-CTLA4 antibody), or Relatlimab (Opdualag; anti-LAG-3).\n5. Participants must have stable disease or concern for progression of their disease on most recent imaging scans yet be continuing on anti-PD1 or anti-PD-L1 therapy, per the treating physician. Participants may continue on anti-CTLA-4 or anti-LAG-3 ICIs if they have already been taking these when assessed to have stable or potentially progressive disease on most recent imaging. Subjects may also discontinue anti-CTLA-4 or anti-LAG-3 ICIs and remain eligible as long as they meet above criteria and continue the anti-PD-1 or anti-PD-L1 component of therapy that they have already been taking.\n6. Participants must have at least one evaluable (measurable) tumor that is radiographically detectable.\n7. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.\n8. Participants must have a life expectancy of at least 6 months.\n9. People who could become pregnant have a confirmed negative urine pregnancy test within 7 days prior to receiving Y-NM600.\n10. Participants who are not surgically or medically sterile must agree to use an acceptable method of contraception, such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence during the study participation and for 6 months after last dose of study drug. Participants who could impregnate their sexual partners must also abstain from intercourse for three weeks after Y-NM600 treatment and agree to use condoms at least 2 months after the last dose of this drug. Participants who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be people who could become pregnant.\n11. The participant has adequate renal function as defined by Cockcroft-Gault calculated creatinine clearance \\>40 ml\u002Fmin\n12. The subject has adequate hepatic function as defined by:\n\n    1. total bilirubin ≤ 1.5 times the upper limit of normal (ULN)\n    2. aspartate transaminase (AST) and alanine transaminase (ALT) less than or equal to 3.0 times the ULN\n13. The participant has adequate hematologic function without Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) injection or transfusion in the prior 7 days, as evidenced by:\n\n    1. an absolute neutrophil count (ANC) greater than or equal to 2000 \u002F μL\n    2. hemoglobin greater than or equal to 8 g\u002FdL\n    3. platelets greater than or equal to 100,000 \u002F μL\n14. For phase 1a, participant must be willing to undergo 2 core needle biopsies that are accessible via ultrasound and\u002For clinical biopsy.\n15. Adequate uptake of 86Y-NM600 (2x red bone marrow) on PET CT imaging.\n16. No grade 2 toxicities that are new compared to baseline and lack a possible alternative explanation (e.g., underlying disease or another known cause) were noted by Day 7 after the 86Y-NM600 infusion. Toxicities with at least a possibly related attribution to disease and\u002For another cause-even if also considered at least possibly related to 86Y-NM600-are permitted.\n17. No Grade ≥ 3 toxicities that are new compared to baseline were noted by day 7 after 86Y-NM600 infusion.\n\nExclusion Criteria:\n\n1. Other concurrent severe and\u002For uncontrolled concomitant medical or psychiatric conditions (e.g., active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol, per investigator discretion.\n2. The participant is taking strong inducers or inhibitors of CYP450 enzymes or drug transporters that cannot be held from at least 30 days prior to administration of 86Y-NM600 through the final 90Y-NM600 infusion without any expected adverse events. Examples include: clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, phenobarbital, phenytoin, rifampicin, and glucocorticoids.\n3. Chemotherapy, radiotherapy, or major surgery within 3 weeks prior to study enrollment (this will be greater than 5 weeks prior to 90Y-NM600 therapy).\n\n   a. For patients receiving prior radiation therapy, the dose to tumor, kidneys, liver, and bone marrow must be recorded, if available.\n4. The participant is pregnant, breastfeeding, or expecting to conceive or could impregnate someone within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment.\n5. Any ongoing or active infection, including active tuberculosis, hepatitis B or C, or known infection with the human immunodeficiency virus (HIV) that is not well controlled (undetectable viral load by PCR) by anti-retroviral therapy.\n6. Concurrent treatment with any other systemic anti-cancer or investigational agents other than an anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-LAG-3 antibody. Subjects cannot be receiving concomitant chemotherapy, experimental therapy or any other therapy not otherwise outlined by the trial for the purposes of anti-cancer treatment.\n\n   b. Palliative external beam radiation therapy may be delivered to patients during this study if deemed necessary and safe by the treating physician.\n\n   c. Participants can be receiving dual immune checkpoint inhibition with an anti-CTLA-4 antibody or an anti-LAG-3 antibody in addition to an anti-PD-1 or anti-PD-L1 therapy.\n7. Patients with a history of or concurrent second primary malignancy within 2 years to study enrollment are excluded, with the exception of patients who have had definitive treatment of a primary skin basal cell, skin squamous cell carcinomas, or localized low or intermediate risk prostate cancer - these subjects are eligible 3 months after completion of definitive treatment for that prior cancer.\n8. Participants that have had total body or hemibody irradiation, or have had prior systemic radioisotope therapy (except for benign thyroid disease)\n9. Any condition requiring the use of immunosuppression, excluding rheumatologic conditions or endocrine conditions treated with stable doses of corticosteroids (equivalent to prednisone 10 mg daily)\n10. Ongoing hemodialysis or peritoneal dialysis\n11. Any known medical condition that predisposes the subject to uncontrolled bleeding such as hemophilia or clotting factor deficiencies\n12. Participants with known genetic conditions causing pre-disposition to RT toxicity (i.e.: Li-Fraumeni, ataxia telangiectasia mutated (ATM) deficiency, active scleroderma, active inflammatory bowel disease, active systemic lupus)\n13. Patients with an implanted defibrillator or with an implanted pacemaker and pacemaker dependency for rate or rhythm control\n14. Patients with repeated demonstration on two EKGs of a QTcF interval greater than 470 milliseconds or use of medications known to prolong the QT\u002FQTc interval\n15. Participants who cannot provide independent, legal, informed consent","ALL",{"count":56,"type":23},60,"INTERVENTIONAL",[59],"PHASE1","Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.",[62],"Metastatic Cancer","2026-08-17",{"date":35,"type":38},{"date":66,"type":23},"2026-11-01",{"date":68,"type":23},"2028-09",{"name":44,"class":45},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":57,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100598581","aces-sirt1-and-premature-vascular-aging-in-humans-100598581","NCT07073352","ACEs, SIRT1, and Premature Vascular Aging in Humans","Adverse Childhood Experiences and Premature Vascular Aging in Humans: The Role of SIRT1","Inclusion Criteria:\n\n* 18 - 30 years\n* ACE score of 0 OR ≥4 (Aim 1); ACE score ≥4 (Aim 2)\n\nExclusion Criteria:\n\n* Resting arterial blood pressure \\>140\u002F90 mmHg\n* BMI ≥30 kg\u002Fm2 and\u002For weight unstable (\\>2.27 kg change) last 6 month\n* Cardiovascular, metabolic, or pulmonary disease\n* Cardiovascular or metabolic prescription drug use\n* Vasoactive antidepressant drug use (SSRIs and clonidine)\n* Currently pregnant or breastfeeding\n* Heavy alcohol consumption (AUDIT screening)\n* Use of illicit drugs\n* Current tobacco use\n* Regular vigorous (\\>6 MET s) aerobic exercise (\\>4 bouts\u002Fweek, \\>30 min\u002Fbout)\n* Dietary supplementation with antioxidants or habitual use of NSAIDs","30 Years",{"count":79,"type":23},30,[81],"NA","Adverse childhood experiences (ACEs) are directly related to cardiovascular morbidity and mortality, and impaired vascular endothelial function (VEF) is an independent predictor of future cardiovascular disease (CVD) risk \\[1, 2\\]. Previous work from our lab (IRB 202010095) and others \\[3\\] demonstrates impaired VEF in young adults with prior exposure to ACEs even in the absence of clinical CVD risk factors. Sirtuin 1 (SIRT1) is a class III histone deacetylase (HDAC) that plays a role in regulating vascular homeostasis and reductions in SIRT1 are associated with age-related endothelial dysfunction \\[4\\]. We have shown that ACEs-related impairments in VEF are accompanied by reductions in SIRT1 \\[5\\]. However, the mechanisms by which ACE exposure promotes VEF remain unknown. The goal of this project is to establish proof of concept that alterations in vascular SIRT1 expression and activity mediate premature vascular aging in individuals with \\>=4 ACEs compared to those with 0 ACEs and that, because NAD+ is an essential substrate for SIRT1, increasing NAD+ bioavailability will restore VEF in those with \\>=4 ACEs.\n\nThus, we will use a robust translational approach coupling in vivo and in vitro measures of endothelial function, inflammation, oxidative stress, and SIRT1 expression and activity in young adults with (n=30-35) versus without (n=30-35) ACE exposure in a cross-sectional study, and during a randomized controlled trial employing a novel 4-week nicotinamide riboside (NR) supplementation approach to increase SIRT1 activity by increasing cellular NAD+ in ACE+ (n=15\u002Fgroup) to accomplish the following specific aims:\n\n1. Determine the mechanisms by which ACE exposure alters the regulation of VEF by SIRT1. We hypothesize that compared to those without ACEs (ACE-), ACE+ will have (H1a) elevated endothelial oxidative stress and inflammation, (H1b) accompanied by reduced endothelial SIRT1 expression and increased p66SHC expression and acetylation of p65 and p53, (H1c) in association with lower VEF.\n2. Determine how targeting SIRT1 by increasing NAD+ bioavailability affects VEF in young adults with ACEs. We hypothesize that systemic NR supplementation will (H2a) augment cellular SIRT1 activity and (H2b) improve VEF in ACE+.\n\n\\[1\\] Felitti, V.J., Anda, R.F., Nordenberg, D., Williamson, D.F., Spitz, A.M., Edwards, V., Koss, M.P., \\& Marks, J.S. (1998). Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The adverse childhood experiences (ace) study. American Journal of Preventive Medicine, 14(4), 245-258. https:\u002F\u002Fdoi.org\u002F10.1016\u002FS0749-3797(98)00017-8. \\[2\\] Jenkins, N.D.M., \\& Robinson, A.T. (2022). How do adverse childhood experiences get under the skin to promote cardiovascular disease? A focus on vascular health. Function (Oxf), 3(4), zqac032. PMC9279110. 10.1093\u002Ffunction\u002Fzqac032. \\[3\\] Rodriguez-Miguelez, P., Looney, J., Blackburn, M., Thomas, J., Pollock, J.S., \\& Harris, R.A. (2022). The link between childhood adversity and cardiovascular disease risk: Role of cerebral and systemic vasculature. Function. 10.1093\u002Ffunction\u002Fzqac029. \\[4\\] Thompson, A. M., Wagner, R., \\& Rzucidlo, E. M. (2014). Age-related loss of SirT1 expression results in dysregulated human vascular smooth muscle cell function. American Journal of Physiology-Heart and Circulatory Physiology, 307(4), H533-H541. \\[5\\] Jenkins, N.D.M., Rogers, E.M., Banks, N.F., Tomko, P.M., Sciarrillo, C.M., Emerson, S.R., Taylor, A., \\& Teague, T.K. (2021). Childhood psychosocial stress is linked with impaired vascular endothelial function, lower sirt1, and oxidative stress in young adulthood. Am J Physiol Heart Circ Physiol, 321(3), H532-H541. PMC8461842. 10.1152\u002Fajpheart.00123.2021",[84,85],"Adverse Childhood Experiences","Endothelial Dysfunction",{"date":35,"type":38},{"date":88,"type":38},"2025-03-27",{"date":90,"type":23},"2027-06-30",{"name":44,"class":45},2,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":57,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100546267","phase-1-dose-escalation-trial-of-mesenchymal-stromal-cells-in-patients-with-medical-xerostomia-100546267","NCT06392711","Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","UW23129: A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","Inclusion Criteria:\n\n* Xerostomia, defined as an unstimulated salivary flow \\\u003C1.2 mL in 5 minutes documented at any time following xerostomia diagnosis and prior to enrollment\n* Xerostomia not resulting from radiotherapy (medical xerostomia)\n* ≥ 18 years of age, ≤ 90 years of age\n* Karnofsky performance status ≥ 70, patient eligible for bone marrow aspirate with wakeful anesthesia\n* Willing and able to give informed consent\n* Radiographically confirmed bilateral submandibular glands\n* If female of childbearing potential, negative pregnancy test\n* Males and females of childbearing potential willing to use acceptable contraception\n* Laboratory Values (within 28 calendar days of enrollment):\n\n  * Hgb ≥ 9 g\u002FdL (5.58 mmol\u002FL)\n  * Platelets ≥ 100,000\u002FµL\n  * ANC ≥ 1000\u002FµL\n  * Lymphocytes ≥ 800\u002FµL\n  * PT\u002FINR and PTT within normal limits based on age\u002Fsex\n\nExclusion Criteria:\n\n* Patients with one submandibular gland\n* Sialolithiasis\n* Poorly-controlled diabetes mellitus (HbA1c ≥ 7%)\n* Patients who initiated any diuretic therapy before developing dry mouth symptoms and are still on diuretic therapy and the referring provider believes the dryness symptoms are driven by diuretic use\n* Untreated oral candidiasis based on physical exam at enrollment\n* Malignancy within the last 2 years (except adequately treated stage I lung cancer, low risk prostate cancer that has been treated or is undergoing active surveillance, adequately treated non-melanoma skin cancer, adequately treated DCIS, or adequately treated stage I cervical cancer)\n* For patients on immunosuppressive therapy, must be on stable dose of immunosuppressive therapy for at least 2 months, allowing for dose adjustments for blood levels of drugs\n* Transfusion dependency\n* Life expectancy ≤ 6 months as determined by the investigator\n* Use of investigational drugs, biologics, or devices within 30 calendar days prior to enrollment\n* Pregnant or lactating women or those who plan to become pregnant during the study\n* Not suitable for study participation due to other reasons at discretion of investigators.\n* Enrollment in another clinical study possibly interfering with the endpoints of this study","90 Years",{"count":102,"type":23},36,[59],"The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells (MSCs) into salivary glands. The main question it aims to answer is whether injection of MSCs into salivary glands results in any improvement in dry mouth.\n\nParticipants will:\n\n* have bone marrow collected using a needle\n* undergo a salivary gland ultrasound\n* complete questionnaires\n* receive an injection of the bone marrow cells into a salivary gland",[106,107,108],"Xerostomia","Graft-versus-host-disease","Sjogren's Disease",{"date":35,"type":38},{"date":111,"type":38},"2024-10-04",{"date":113,"type":23},"2028-11",{"name":44,"class":45},{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":54,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":46},"100533456","growing-little-peapods-study-100533456","NCT06226051","Growing Little PEAPODS Study","Growing Little PEAPODS Study: Association Between Prematurity and Body Composition, Nutrition Practices, and Neurodevelopmental Outcomes","Neonate Inclusion Criteria:\n\n* Born inpatient at Meriter Hospital, Inc. at or above 22 gestational weeks. Upper limit is 32 weeks 6 days GA (possible gestational age range from 22w0d-32w6d)\n\nNeonate Exclusion Criteria:\n\n* Known genetic condition that impacts neurodevelopmental outcomes or brain structure development\n* Multiple major congenital anomalies\n* Per the investigator's opinion, the subject will likely require transfer to American Family Children's Hospital (AFCH) before 36 weeks PMA\n\n  * Any neonate who enrolls in the study and then unexpectedly requires transfer to AFCH before 36 weeks PMA will be excluded from the study if they are unable to obtain at least one body composition measurement before transfer. Body composition data points can only be collected at Meriter Hospital due to the location of PEAPOD\n\nBirthing Parent Inclusion Criteria:\n\n* Birthing parent must speak English or Spanish due to consent documents\n* Able to understand and willing to sign a written informed consent document\n* Primary caregiver of a neonate who is eligible to participate in the study\n* Agrees to enroll neonate into the study\n* Willing to comply with all study procedures and be available for the duration of the study\n* Age 15 or older\n\nBirthing Parent Exclusion Criteria:\n\n* Subject is unable to provide informed consent, including subjects in foster care and subjects within state custody\n* Does not plan to maintain custody of the child after birth, such as in instances of adoption or surrogacy","22 Weeks","32 Weeks",{"count":125,"type":23},120,"The goal of this clinical trial is to learn more about how the food and nutrition babies receive while in the Neonatal Intensive Care Unit (NICU) influences their ability to gain weight and fat-free mass, and their future growth and development.\n\nParticipants will:\n\n* have body growth measurements collected using the PEAPOD device\n* have nutritional information collected, and\n* be followed for neurodevelopmental outcomes\n\nParticipants can expect to be in the study for 36 months.",[128,129,130,131,132],"Premature Birth","Premature Infant","Premature","Intrauterine Growth Restriction","Small for Gestational Age at Delivery",{"date":35,"type":38},{"date":135,"type":38},"2024-09-04",{"date":137,"type":23},"2028-01",{"name":44,"class":45},{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":17,"sex":54,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":46},"100605135","opti-gait-wearable-gait-tracker-100605135","NCT07158580","Opti Gait Wearable Gait Tracker","Opti Gait Wearable Gait Tracker: Pilot Trial l With Healthy Older Adults","Inclusion Criteria:\n\n* Aged 65 years and older\n* Able to speak and understand English,\n* Able to provide consent\n\nExclusion Criteria:\n\n* Current or recent (\\\u003C 1 year) major psychiatric condition\n* Significant medical condition such that usability evaluation could pose substantial health or safety risk\n* Individuals with an activated power of attorney will be excluded from the study","65 Years",{"count":148,"type":23},20,"The purpose of this observational study is to test a shoe mounted gait monitoring device that was refined with the input of older adults and assess the efficacy of the refinements through a series of tests that involve walking with and without the device.",[151],"Seniors","NOT_YET_RECRUITING","2026-08-14",{"date":155,"type":38},"2026-08-18",{"date":157,"type":23},"2026-09",{"date":159,"type":23},"2027-09",{"name":44,"class":45},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":57,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100645223","the-lucida-project-100645223","NCT07678242","The Lucida Project","Inclusion Criteria - all participants:\n\n* Age 18 to 84\n* Elevated depressive symptoms: PHQ-9 ≥ 10; Healthy controls: PHQ-9 \\\u003C5\n\nInclusion Criteria - randomized participants:\n\n* Proficient in English to try to unsure understanding of study requirement, consent forms and questionnaires that can often us medical terms not routinely used in general conversation.\n* Able to provide informed consent\n* Have access to a smartphone that can download apps from Google Play or the Apple App Store\n* Ability to receive text messages\n* Indicate interest in participation after being informed of restrictions to payment\n\nExclusion Criteria:\n\n* Regular daily meditation practice for past 6 months or regular weekly meditation practice for past 12 months\n* Attended a meditation retreat or a yoga\u002Fbody practice retreat with a significant meditation component\n* Previous use of Healthy Minds Program app\n* Current suicidal intent and\u002For high self-injury risk (determined by PHQ-9 item 9 and BDI item 9)\n* Self-reported history of psychosis\n* Self-reported history of mania\n* Living or traveling outside the US during the whole study participation period (trips outside US after the interview phase is not an exclusion)\n* Hearing impairments\n* Prior participation\n* Self report pregnancy","84 Years",{"count":169,"type":23},1500,[81],"The purpose of this clinical trial is to learn about the impact of the Healthy Minds Program (HMP) on measurements of well-being. The main question it aims to answer is:\n\n* Does use of HMP reduce symptoms of depression?\n\nParticipants will complete a 4-week well-being program.",[173],"Depression Disorder","2026-08-12",{"date":153,"type":38},{"date":177,"type":23},"2026-10",{"date":179,"type":23},"2028-10",{"name":44,"class":45},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":17,"sex":54,"minAge":187,"maxAge":19,"enrollmentInfo":188,"targetDuration":4,"studyType":57,"phases":190,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":46},"100639610","testing-and-evaluating-an-interactive-media-use-journal-for-adolescents-100639610","NCT07620964","Testing and Evaluating an Interactive Media Use Journal for Adolescents","Inclusion Criteria:\n\n* English speaking\n* has internet access\n* in the United States\n\nExclusion Criteria:\n\n* youth under the age of 13 years\n* over the age of 18 years","13 Years",{"count":189,"type":23},50,[81],"The goal of this study is to test the feasibility and acceptability of an Interactive Media Use Journal (IMUJ) co-developed with youth.\n\nThis study is part of a larger effort using Intervention Mapping to co-develop this resource, test it for feasibility and acceptability via this proposed protocol, and then eventually disseminate the resource in partnership with the American Academy of Pediatrics.\n\n50 participants between the ages of 13-18 will be recruited for this study",[193,194],"Social Media","Adolescent Behavior",[196,197,198,199,200],"social media engagement","health","behavior change","habit","intervention mapping",{"date":153,"type":38},{"date":203,"type":38},"2026-07-19",{"date":205,"type":23},"2026-08",{"name":44,"class":45},{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":57,"phases":215,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100638973","a-well-being-intervention-for-people-with-ibs-100638973","NCT07600047","A Well-Being Intervention for People With IBS","Inclusion Criteria:\n\n* Men and women currently diagnosed with Irritable Bowel Syndrome (IBS) by a healthcare provider.\n* Able to read and write in English.\n* Willing to complete questionnaires and participate in either the intervention or control group.\n* Capable of providing informed consent.\n* Must be a UW Health patient or referred through UW Digestive Health Center.\n\nExclusion Criteria:\n\n* Individuals with cognitive impairments or reading difficulties that would interfere with understanding study materials or completing assessments.\n* Individuals unable to provide informed consent.\n* Prior participation in a similar intervention study.\n* Non-English speakers (since study materials are in English)",{"count":214,"type":23},150,[81],"The purpose of this randomized behavioral clinical trial is to examine whether a well-being intervention can improve both psychological well-being and physical outcomes in adults with Irritable Bowel Syndrome (IBS). The study aims to assess whether this intervention decreases anger, anxiety, and depression; increases self-esteem, empathy, and hope; and improves quality of life indicators such as IBS symptom severity, sleep quality, fatigue, and diet. Participants can expect to be on study for up to 9 months.",[218],"Irritable Bowel Syndrome",[220],"well being",{"date":222,"type":38},"2026-08-13",{"date":157,"type":23},{"date":225,"type":23},"2027-08",{"name":44,"class":45},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":57,"phases":237,"briefSummary":238,"conditions":239,"keywords":243,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":249,"locationsCount":46},"100531932","the-oh-happy-day-class---digital-connections-ohdc-dc-a-pilot-study-100531932","NCT06206226","The Oh Happy Day Class - Digital Connections (OHDC-DC): A Pilot Study","The Oh Happy Day Class - Digital Connections (OHDC-DC): an Exploratory Pilot Study","OHDC-DC","Inclusion Criteria:\n\n* African-American\n* Age 18 and older\n* Experiencing depression (as evidenced by a score of 5 or higher on the PHQ-9)\n* Own a mobile phone\n\nExclusion Criteria:\n\n* Individuals who are currently receiving psychotherapy\n* Individuals who are presently experiencing suicidal ideation\n* Individuals who started psychotropic medication less than three months prior to the start of the OHDC will be excluded from the study\n* Participants scoring 25 or higher on the PHQ-9 will be screened out",{"count":236,"type":23},8,[81],"The goal of this clinical trial is to see if a mobile phone app can deliver depression treatment to African Americans who are depressed. The main question it aims to answer is if this treatment is effective in reducing symptoms of depression.\n\nParticipants will attend six 90-minute weekly classes via an app on their phone, and will be asked to complete surveys every week. Participants can expect to be in the study for four months.",[240,241,242],"Depression","Depressive Disorder","Depressive Symptoms",[244],"African American",{"date":153,"type":38},{"date":205,"type":23},{"date":248,"type":23},"2027-02",{"name":44,"class":45},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":57,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":46},"100484769","dementia-care-partner-hospital-assessment-tool-100484769","NCT05592366","Dementia Care Partner Hospital Assessment Tool","Adapting and Testing the Care Partner Hospital Assessment Tool for Use in Dementia Care","Inclusion Criteria:\n\n* Provide unpaid care to a hospitalized adult relative or partner to help them take care of themselves because of ADRD\n* 18 years or older\n\nExclusion Criteria:\n\n* Non-English speaking",{"count":258,"type":23},128,[81],"The purpose of this study is to see whether an adapted questionnaire called the Care Partner Hospital Assessment Tool (CHAT) for care partners of hospitalized patients living with Alzheimer's disease and related dementias (ADRD) (CHAT-AD) can help people with dementia receive better care after they go home from the hospital. Participants will be a care partner ('family member or friend') who provides unpaid care to a hospitalized adult relative or partner to help them take care of themselves because of dementia. Participants can expect to be in this study for 14 days.",[262,263],"Alzheimer Disease","Dementia",{"date":153,"type":38},{"date":266,"type":38},"2024-04-02",{"date":268,"type":23},"2027-05",{"name":44,"class":45},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":146,"enrollmentInfo":277,"targetDuration":4,"studyType":57,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":46},"100652053","lapbox-manual-containment-system-100652053","NCT07767968","LapBox® Manual Containment System","Evaluation of Leak Integrity of the LapBox® Manual Containment System During Laparoscopic Surgery","Inclusion Criteria:\n\n* Participants who require laparoscopic hysterectomy or myomectomy for management of uterine fibroids\n\nExclusion Criteria:\n\n\\-",{"count":278,"type":23},24,[81],"This study to evaluate the leak integrity of the LapBox Manual Containment System for laparoscopic hysterectomy and myomectomy. The goal is to determine the integrity of this containment system in order to increase surgical safety. 30 adult females who require laparoscopic hysterectomy or myomectomy for management of uterine fibroids will be enrolled and will be on study the day of surgery.",[282],"Surgery",[284,285,286,287],"laparoscopic hysterectomy","laparoscopic myomectomy","uterine fibroids","morcellation","2026-08-11",{"date":63,"type":38},{"date":157,"type":23},{"date":292,"type":23},"2027-07",{"name":44,"class":45},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":57,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":46},"100591071","well-being-skills-for-reentry-100591071","NCT06975657","Well-being Skills for Reentry","Community-engaged Research to Promote Mental Health and Successful Reentry Outcomes Following Incarceration","Inclusion Criteria:\n\n* Age 18 or older\n* Formerly incarcerated in a local jail, state or federal prison\n* Can read, speak and understand English\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Suicidal ideation with some intent to act or with a specific plan and intent\n* Active psychosis\n* Daily or nearly daily use (over the past 3 months) of the following substances: cocaine, amphetamines, inhalants, sedatives or sleeping pills, hallucinogens, or opioids",{"count":56,"type":23},[81],"The goal of this clinical trial is to learn if a mindfulness skills training program has mental health benefits for people returning to the community following incarceration. The main questions it aims to answer are:\n\n* Does mindfulness skills training improve symptoms of anxiety and depression?\n* Do participants find this mindfulness program to be acceptable and feasible to participate in?\n\nResearchers will compare outcomes for participants in the mindfulness training program to those in a waitlist control group who will receive the mindfulness program after the end of the study.\n\nParticipants will:\n\n* Complete an initial intake visit, consisting of an interview and questionnaires\n* Randomly be assigned to a mindfulness group or a waitlist control group\n* Participate in weekly mindfulness classes for 6 weeks (mindfulness group only)\n* Complete a set of questionnaires after the conclusion of the mindfulness classes\n* Complete a set of questionnaires and an interview 2 months after the conclusion of the mindfulness classes",[305],"Formerly Incarcerated Adults",{"date":222,"type":38},{"date":308,"type":38},"2026-01-12",{"date":310,"type":23},"2027-11-30",{"name":44,"class":45},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":146,"enrollmentInfo":319,"targetDuration":4,"studyType":57,"phases":320,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":46},"100569280","phase-1-the-recap2-study-midazolam-and-psilocybin-100569280","NCT06692192","The RECAP2 Study: Midazolam and Psilocybin","Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)","Inclusion Criteria:\n\n* Age 18 to 65 years at screening, of any identified gender and racial\u002Fethnic group\n* Physically healthy; does not meet criteria for an exclusionary medical condition\n* English-speaking (able to provide consent and complete questionnaires)\n* Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder\n* Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)\n\nExclusion Criteria:\n\n* Exclusionary DSM-5 psychiatric diagnosis and\u002For active suicidal ideation\n* Exclusionary medical conditions\n* Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)\n* Clinically significant electrocardiogram (ECG)\n* Use of psychotropic or CNS-altering medications within 3 months of screening\n* Hypertension or tachycardia",{"count":56,"type":23},[59],"The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.\n\nResearchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.\n\nParticipants will:\n\n* Receive one of four possible combinations of medications\n* Undergo an MRI\n* Complete questionnaires\n* Undergo transcranial magnetic stimulation (TMS) and EEG",[323],"Psilocybin",[325],"sub-optimal wellbeing",{"date":222,"type":38},{"date":328,"type":38},"2025-08-07",{"date":330,"type":23},"2027-12",{"name":44,"class":45},{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":57,"phases":342,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":355,"leadSponsor":357,"locationsCount":46},"100651859","phase-2-combination-therapy-using-durvalumab-and-histotripsy-for-treatment-of-intrahepatic-cholangiocarcinoma-100651859","NCT07766187","Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma","Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma (CODAH Trial)","CODAH","Inclusion Criteria:\n\n* Participant diagnosed with histologically confirmed intrahepatic cholangiocarcinoma\n\n  * Participant demonstrates disease control following 18 weeks of chemotherapy (gemcitabine and\u002For cisplatin) and immunotherapy (durvalumab) as part of standard of care first line regimen.\n\n    * Participants are allowed to be on maintenance durvalumab therapy following disease control at 18 weeks prior to enrollment into the study.\n  * All participants must have prior biopsy confirming diagnosis of cholangiocarcinoma.\n* Participant has iCCA tumor burden appropriate for biopsy and histotripsy treatment\n\n  * Participant able to undergo liver biopsy of Index Tumor.\n\n    * Index Tumor will be a predetermined non-histotripsy tumor in patients with multifocal disease, or a predetermined region of intentionally untreated tumor in patients with solitary disease.\n  * Participant to have iCCA deemed targetable for histotripsy.\n\n    * Participants with solitary tumor must have longest dimension ≥ 2.0 cm to allow for planned region of intentionally untreated Target Tumor for Index Tumor.\n* Participants' iCCA is considered unresectable or patient is a non-surgical candidate\n* Participant can undergo general anesthesia.\n* Participant has a Child-Pugh Score of A or B (up to B8).\n* Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2 at baseline screening.\n* Participant meets the following functional criteria, ≤7 days prior to the planned histotripsy procedure date\n\n  * Liver function: Alanine transaminase (ALT) and Aspartate transaminase (AST) \\\u003C2.5x upper limit of normal (ULN) and\u002For bilirubin \\\u003C2.5 ULN.\n  * Renal function: serum creatinine \\\u003C2x ULN.\n  * Hematologic function: Absolute neutrophil count \\>1,000\u002FuL and platelet \\>50,000\u002FuL, hemoglobin \\>8.0 g\u002FdL.\n* Participant has an International Normalized Ratio (INR) score of \\\u003C3.0, ≤7 days prior to the planned histotripsy procedure date.\n* Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to registration.\n* Females of childbearing potential who are sexually active with a male able to father a child must be willing to abstain from heterosexual vaginal intercourse or use an effective method(s) of contraception from the time of informed consent, during the study and for up to 14 months after the last dose of study drug(s). Males able to father a child must be willing to abstain from heterosexual vaginal intercourse or to use an effective method(s) of contraception from initiation of treatment, during the study and for up to 11 months after the last dose of study drug(s).\n* Ability of the participant to understand and comply with study procedures for the entire length of the study, as determined by the enrolling physician or protocol designee.\n\nExclusion Criteria:\n\n* Participant is pregnant or planning to become pregnant or nursing (lactating) during the trial period.\n* Participant is enrolled in another investigational trial and\u002For is taking investigational medication or treated with an investigational device ≤30-days prior to planned histotripsy procedure date.\n* In the Investigator's opinion, the subject has co-morbid disease(s) or condition(s) that would cause undue risk and preclude safe histotripsy treatment, including but not limited to interstitial lung disease, including history of interstitial lung disease or non-infectious pneumonitis.\n* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. .\n* Participant has major surgical procedure or significant traumatic injury ≤2 weeks prior to the planned treatment or not fully recovered (CTCAE grade 1 or better) from side effects\u002Fcomplications of such procedure or trauma.\n* Participant has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse effects (exceptions for alopecia, grade 2 neuropathy, grade 2 hypothyroidism, grade 2 hypoadrenalism) related to previous anti-cancer therapy. Please refer to inclusion criteria for lab-based enrollment parameters.\n* Participant has a history of bleeding disorders (e.g. von Willebrand disease) or subject is suspected to have a bleeding disorder.\n* Participant has uncorrectable coagulopathy.\n* In the opinion of the Investigator, histotripsy is not a treatment option for the subject.\n* Participant has a concurrent condition that, in the investigator's opinion, could jeopardize the safety of the subject or compliance with the protocol.\n* Participants' tumor(s) is not targetable per discretion of radiologist.\n* Participant has a known sensitivity to contrast media and cannot be adequately pre-medicated.\n* Participants' Target Tumor(s) has\u002Fhave had prior locoregional therapy (e.g. ablation, embolization, radiation).\n* History of solid organ or allogeneic bone marrow transplantation.\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial.\n* Significant dementia or other mental condition that precludes the participant's ability to consent to the study.\n* Untreated central nervous system (CNS) metastasis. Screening of asymptomatic patients for CNS metastasis is not required for enrollment.\n* Live vaccine administration within 28 days of planned initial dose of durvalumab.",{"count":341,"type":23},12,[343],"PHASE2","The purpose of this research is to evaluate whether adding histotripsy to maintenance durvalumab increases immune response and to assess the safety of this combination for participants with advanced intrahepatic cholangiocarcinoma (iCCA). Histotripsy is a non-invasive, non-thermal treatment that uses focused ultrasound energy to destroy tumor tissue. 12 people will be enrolled in this study.",[346],"Intrahepatic Cholangiocarcinoma",[348,349,350,351],"iCCA","histotripsy","tumor microenvironment","immunotherapy","2026-08-10",{"date":153,"type":38},{"date":205,"type":23},{"date":356,"type":23},"2032-08",{"name":44,"class":45},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":57,"phases":367,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":378,"locationsCount":379},"100583773","the-tick-app-changing-behaviors-with-educational-messaging-100583773","NCT06880692","The Tick App: Changing Behaviors With Educational Messaging","The Use of Ecological Momentary Assessments to Assess Tick-borne Disease Risk","Inclusion Criteria:\n\n* Will to participate in 7 days worth of daily activity logs within the Tick App.\n* be able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Completes less than 7 days worth of daily logs or completes 7+ daily logs but not within 12 months.",{"count":366,"type":23},40000,[81],"The goal of this work is to evaluate the use of ecological momentary assessments as a tool to assess risk and risk factors for tick encounters and tick-borne diseases. This study will be conducted across the United States, with a focus the upper Midwest and Northeast and with a focus on Wisconsin and will enroll up to 1000 people.",[370],"Tick Bites",[372,198,373],"tick education","tick bite prevention",{"date":222,"type":38},{"date":376,"type":38},"2020-03-31",{"date":292,"type":23},{"name":44,"class":45},4,{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":54,"minAge":4,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":57,"phases":390,"briefSummary":391,"conditions":392,"keywords":395,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":46},"100575403","evaluation-of-pediatric-ecart-implementation-100575403","NCT06771830","Evaluation of Pediatric eCART Implementation","A Rapid Diagnostic of Risk in Hospitalized Pediatric Patients to Improve Outcomes Using Machine Learning","Inclusion Criteria (pediatric patients):\n\n* All pediatric patients scored on pediatric eCART (or eligible for scoring on either algorithm in the pre-implementation period) will be screened for study eligibility.\n* Patients eligible for pediatric eCART scoring include pediatric (\\\u003C18 years of age) patients\n* Inpatient locations\n\nExclusion Criteria (pediatric patients):\n\n* Patients who are ineligible for pediatric eCART scoring\n* Neonates and birth encounters will be excluded from the pediatric eCART study\n\nInclusion Criteria (nurse clinicians):\n\n* UW Health nurses who interact with eCART during patient care\n\nExclusion Criteria (nurse clinician):\n\n* UW Health nurses no longer employed at UW Health","17 Years",{"count":389,"type":23},30000,[81],"This is a study comparing 3 years of retrospective data (pre-implementation) to 2 years of prospective data after the implementation of a pediatric version of Electronic Cardiac Arrest Risk Triage (pediatric eCART), a clinical decision support (CDS) tool that uses electronic health records (EHR) to identify patients with high risk for life threatening outcomes. Up to 30,000 encounters with pediatric patients will be assessed. Acceptability of the pediatric eCART intervention will also be measured from pediatric nurse clinicians.",[393,394],"Pediatric ALL","Sepsis",[396,397,398,399,400],"machine learning","artificial intelligence","clinical decision support","triage","electronic medical records",{"date":222,"type":38},{"date":403,"type":38},"2025-12-01",{"date":330,"type":23},{"name":44,"class":45},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":20,"enrollmentInfo":413,"targetDuration":4,"studyType":57,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":46},"100598070","phase-2-painful-post-operative-hip-study-100598070","NCT07066709","Painful Post-Operative Hip Study","Identifying and Managing Pain Generators in Patients With Persistent Post-hip Arthroscopy Pain Using FDG PET\u002FMRI","Inclusion Criteria:\n\n* Age 18-45\n* History of unilateral hip arthroscopy\n* Does not have evidence of fracture, infection, or malignancy at 6 months post-hip arthroscopy\n* Does not have evidence of depression or other major mental health conditions before the index hip arthroscopy\n* Does not have persistent pain that requires opioid use, or does not have a history of opioid abuse\n* Does not have any comorbidity results in systemic disease limiting function (ASA physical status classification \\>3)\n* Not currently pregnant\n* Presents with persistent pain (≥4\u002F10 on NRS) for at least 6 months post-hip arthroscopy\n* Undergo a revision hip arthroscopy with no surgical history on the contralateral limb\n\nExclusion Criteria:\n\n* No unilateral hip arthroscopy\n* Evidence of fracture, infection, or malignancy at 6 months post-hip arthroscopy\n* Evidence of depression or other major mental health conditions before the index hip arthroscopy\n* Has persistent pain that requires opioid use, or has a history of opioid abuse\n* Has any comorbidity results in systemic disease limiting function (ASA physical status classification \\\u003C3)\n* Currently pregnant",{"count":414,"type":23},15,[343],"The goal of this clinical trial is to learn if the hips of people who undergo revision hip arthroscopy look different from the hips of people whose hip pain is resolved with the first hip arthroscopy and of people who choose the steroid injection for pain management.\n\nParticipants will complete one PET\u002FMRI scan.",[418],"Unilateral Hip Arthroscopy",{"date":288,"type":38},{"date":421,"type":38},"2026-01-21",{"date":423,"type":23},"2026-11",{"name":44,"class":45},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":57,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":443,"locationsCount":46},"100651529","clinical-evaluation-of-a-treatment-planning-software-and-oncology-information-system-for-proton-therapy-100651529","NCT07759999","Clinical Evaluation of a Treatment Planning Software and Oncology Information System for Proton Therapy","UW26028: Clinical Evaluation of a Treatment Planning Software and Oncology Information System for Proton Therapy","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of consent.\n* Participant is deemed clinically appropriate for standard-of-care proton therapy by treating radiation oncologist and will not require anesthesia for therapy.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participant has contraindications to proton therapy (per standard clinical guidelines).\n* Participant is unable to comply with routine treatment workflow or follow-up.\n* Participants who will be treated with a radiation plan of 5 fractions or fewer.",{"count":433,"type":23},180,[81],"Researchers are doing this study to better understand how certain treatment planning and clinical workflow software systems support the delivery of standard-of-care proton radiation therapy.\n\nThe main question it aims to answer is how well the software works in the workflow.\n\nParticipants will receive proton therapy.",[437],"Proton Therapy","2026-08-06",{"date":174,"type":38},{"date":441,"type":38},"2026-07-15",{"date":159,"type":23},{"name":44,"class":45},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":17,"sex":54,"minAge":450,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":57,"phases":454,"briefSummary":455,"conditions":456,"keywords":457,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":463,"leadSponsor":464,"locationsCount":46},"100650968","evaluating-the-impacts-of-informal-tick-and-tickborne-disease-educational-tools-on-children-100650968","NCT07756606","Evaluating the Impacts of Informal Tick and Tickborne Disease Educational Tools on Children","Inclusion Criteria:\n\n* children aged 6-12 years old\n\nExclusion Criteria:\n\n* less than 6 years old or greater than 12 years old","6 Years","12 Years",{"count":453,"type":23},1000,[81],"The purpose of this study is to evaluate the impacts of informal educational tools used by the Midwest Center of Excellence for Vector-Borne Disease in collaboration with the Wisconsin Department of Health Services. Children aged 6-12 will receive an educational activity about ticks. They will be asked questions before and after the activity and will participate for between 30-60 minutes.",[370],[458,459,460],"education","children","prevention",{"date":352,"type":38},{"date":157,"type":23},{"date":177,"type":23},{"name":44,"class":45},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":473,"enrollmentInfo":474,"targetDuration":4,"studyType":57,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":485,"leadSponsor":486,"locationsCount":46},"100645252","overnight-thalamic-tes-ti-to-modulate-sleep-spindles-in-individuals-with-schizophrenia-spectrum-disorders-and-matched-healthy-controls-100645252","NCT07680114","Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls","A Pilot Feasibility Study of Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls","ONSETS","Inclusion Criteria (all participants):\n\n* U.S. citizen or holding permanent resident status\n* English-speaking\n\nInclusion Criteria (Participants with SSD):\n\n* DSM-5 schizophrenia spectrum disorder (SSD) diagnosis, defined as schizophrenia, schizoaffective disorder, or schizophreniform disorder (confirmed by clinical interview and\u002For chart review)\n* Chronic illness, defined as diagnosis of SSD for at least 1 year\n* Clinically stable outpatient (no psychiatric hospitalization in past 6 months; no change in antipsychotic medication in the past 6 weeks)\n\nInclusion Criteria (Healthy Controls):\n\n* Medically healthy (based on self-report and study team review)\n* Matched to SSD participants on age (±5 years) and sex\n\nExclusion Criteria (all participants):\n\n* Current or past history of clinically significant neurological disorder or acquired neurological disease (e.g., stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified on the structural MRI)\n* Active suicidal ideation, plan, or intent (assessed via PHQ-9 item 9 and follow-up Columbia-Suicide Severity Rating Scale (C-SSRS) Screener; see Safety Response Procedure)\n* Inability to provide informed consent, including inadequate decisional capacity in the judgment of the study team and\u002For study psychiatrist\n* History of head trauma resulting in prolonged loss of consciousness; or a history of \\>3 grade I concussions\n* Current poorly controlled headaches, including intractable or frequent migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Possible pregnancy or plan to become pregnant in the next 6 months (self reported)\n* Any metal in the head\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)\n* Dental implants\n* Permanent retainers\n* Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions\n* Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions\n* Current use of medications known to substantially lower seizure threshold, specifically chlorpromazine, clozapine, bupropion, clomipramine, or maprotiline; or other medications at doses known to substantially lower seizure threshold in the judgment of the PI or Study Psychiatrist\n* Current use of medications known to directly and substantially enhance sleep spindle activity, including benzodiazepines; non-benzodiazepine \"Z-drug\" hypnotics (zolpidem, eszopiclone, zaleplon); barbiturates; and gabapentin or pregabalin, within 2 weeks of the overnight study visits. Other sedating medications used as sleep aids (e.g., trazodone, hydroxyzine, mirtazapine) are permitted provided the regimen is stable across the two overnight visits; dose and timing will be recorded as covariates\n* Current moderate-to-severe alcohol or other substance use disorder (DSM-5) other than nicotine or caffeine\n* Active scalp lesions, broken skin, or skin conditions at planned electrode sites that would preclude safe electrode application\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for up to two hours\n* Regular night-shift work (second or third shift)\n* Sleep apnea or other sleep disorder (self-reported)\n\nExclusion Criteria (Healthy Controls):\n\n* Self-reported history of inpatient psychiatric hospitalization\n* Self-reported current or past diagnosis of schizophrenia or any other psychotic disorder\n* Self-reported first-degree relative with schizophrenia or any other psychotic disorder\n* Self-reported current or past diagnosis of bipolar disorder or major depressive disorder with psychotic features, or current treatment for any psychiatric disorder other than depression or anxiety (handled via the medication rule below)\n* Current use of any psychotropic medication, with the exception of a single SSRI or SNRI taken at a stable dose for at least 6 weeks for depression or anxiety. Current use of antipsychotics, tricyclic antidepressants, mirtazapine, trazodone, lithium or other mood stabilizers, benzodiazepines, non-benzodiazepine hypnotics, other anxiolytics, or stimulants will result in exclusion.","50 Years",{"count":148,"type":23},[81],"This study to find out whether a type of non-invasive electrical brain stimulation called transcranial electrical stimulation with temporal interference (TES-TI) can temporarily change brain activity during sleep-especially sleep spindles (brain rhythms in the \\~8-16 Hz range). The investigators are focusing on the thalamus, a deep brain region that helps coordinate brain activity during non-REM sleep. Sleep spindles are often reduced in schizophrenia, so this study is to see whether TES-TI can change spindle activity in individuals with schizophrenia spectrum disorders (SSD) and in healthy adults. To study this, a structural MRI scan will be used to customize where the stimulation electrodes are placed, and then TES-TI will be applied during one of two overnight sleep lab visits while brain activity is recorded with high-density EEG and standard sleep sensors. The other overnight is a baseline\u002Fcontrol night during which only sham stimulation is delivered. The goal is to determine whether TES-TI during sleep can increase spindle-frequency activity in this population.",[478],"Schizophrenia",[480,481,482],"schizophrenia spectrum disorders","sleep spindles","transcranial electrical stimulation with temporal interference",{"date":352,"type":38},{"date":205,"type":23},{"date":330,"type":23},{"name":44,"class":45},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":494,"enrollmentInfo":495,"targetDuration":4,"studyType":57,"phases":496,"briefSummary":497,"conditions":498,"keywords":501,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":46},"100631253","location--and-frequency-dependent-effects-of-thalamic-temporal-interference-stimulation-during-sleep-100631253","NCT07498270","Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep","CAP-TI","Inclusion Criteria:\n\n* Medically healthy (based on self-report and study team review)\n* U.S. citizen or holding permanent resident status\n* English-speaking (able to provide consent and complete questionnaires)\n\nExclusion Criteria:\n\n* Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified in first MRI)\n* History of inpatient psychiatric hospitalization\n* History of head trauma resulting in prolonged loss of consciousness; or a history of greater than 3 grade I concussions\n* Current history of poorly controlled headaches including intractable or poorly controlled migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Possible pregnancy or plan to become pregnant in the next 6 months (self reported)\n* Any metal in the head\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)\n* Dental implants\n* Permanent retainers\n* Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions\n* Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions\n* Any medication that may alter seizure threshold taken during the study i.e., ADHD stimulants (Adderall, amphetamine); Tricyclic\u002Fatypical antidepressants (amitriptyline, doxepine, imipramine, maprotiline, nortriptyline, bupropion); SSRIs (Escitalopram, Fluoxetine, Sertraline); Antipsychotics (chlorpromazine, clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antivirals (valacyclovir, ritonavir); OTC antihistamines (diphenhydramine, Benadryl)\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for up to two hours\n* Regular night-shift work (second or third shift)\n* Sleep apnea or other sleep disorder (self-reported)","40 Years",{"count":278,"type":23},[81],"This study is to find out whether a type of non-invasive electrical brain stimulation called temporal interference transcranial electrical stimulation (TI-TES) can temporarily change brain activity during sleep, especially sleep spindles (brain rhythms in the \\~8-16 Hz range). Up to 24 healthy participants in Dane County, Wisconsin will be enrolled for 3 overnight study visits. Participants can expect to be on study for approximately 5 weeks, depending on scheduling availability.",[499,500],"Healthy Adult Participants","Healthy Participants",[502,503,504,505,506,507,508,509],"sleep","spindles","non-rapid eye movement","SSD","neurobiology","impairment","brain stimulation","non-invasive stimulation",{"date":352,"type":38},{"date":512,"type":38},"2026-06-05",{"date":514,"type":23},"2028-02",{"name":44,"class":45},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":57,"phases":523,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":531,"locationsCount":46},"100619359","study-to-identify-biomarkers-of-oral-cavity-cancer-response-to-neoadjuvant-immunotherapy-prior-to-definitive-surgery-100619359","NCT07343596","Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery","Inclusion Criteria:\n\n* Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately\n* Age 18 years and older at the time of registration consent\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 within 30 days prior to enrollment\n* Suspected clinical American Joint Committee on Cancer (AJCC) 8th edition stage II-IVB (T2-T4b N0-N3) oral cavity cancer (oral tongue, floor of mouth, buccal, gingival, retromolar trigone, lip, hard palate) amenable to surgical resection. Patients will be consented prior to research biopsy.\n* Primary tumor of at least 2 cm which is amenable to a 250 mm3 (e.g.10 mm x 5 mm x 5 mm) research biopsy, equivalent to one-two forceps biopsies.\n* Patients may not have received prior chemotherapy or immunotherapy for the oral cavity malignancy. Patients must have completed other cancer therapies unrelated to their oral cavity cancer greater than 30 days prior to enrollment.\n* Participants of childbearing potential must agree to contraception during and for 100 days after study therapy.\n* Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to treatment. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for \\> 12 consecutive months.\n* Demonstrate adequate organ function\n\nExclusion Criteria:\n\n* Subjects with a diagnosed auto-immune disease (exceptions: subjects with controlled diabetes mellitus type I, thyroid disease, rheumatoid arthritis, vitiligo and alopecia areata not requiring treatment with immunosuppressants are eligible)\n* Pregnant or breastfeeding\n* Known additional invasive malignancy that is active and\u002For progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease free for at least three years prior to enrollment. This excludes the index oral cavity cancer.\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor.\n* Has received prior radiotherapy treatment or systemic anti-cancer therapy including investigational agents for the HNC under study prior to randomization\u002Fallocation.\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has had previous allogeneic tissue\u002Fsolid organ transplant.\n* Subjects who require systemic treatment doses of corticosteroids (prednisone equivalent greater than or equal to 10 mg daily), or other immunosuppressive drugs\n* Has radiographically detectable (even if asymptomatic and\u002For previously treated) central nervous system metastases and\u002For carcinomatous meningitis as assessed by local site investigator and radiology review\n* Has Grade 3-4 bleeding due to the underlying malignancy\n* Subjects with known human immunodeficiency virus (HIV) infection, active or chronic hepatitis B or hepatitis C infection based on medical history. No testing for HIV, Hepatitis B, or Hepatitis C is required for enrollment. Subjects cannot be positive for HBV DNA, HCV RNA, hepatitis B surface antigen, or anti-hepatitis B core antibody. Patients with Hepatitis B surface antigen negative and anti-hepatis B core antibody positive with undetectable HBV DNA by polymerase chain reaction may enroll.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study.\n* Subjects who cannot provide independent, legal, informed consent",{"count":148,"type":23},[81],"The goal of this clinical trial is to study whether researchers can create a patient-specific tumor system, called a culture vessel, in a timely manner and determine if it can predict how someone will respond to a specific therapy.\n\nParticipants will:\n\n* Undergo a research biopsy\n* Take pembrolizumab per standard of care prior to surgery",[526],"Oral Cavity Cancer",{"date":352,"type":38},{"date":529,"type":38},"2026-04-15",{"date":330,"type":23},{"name":44,"class":45},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":473,"enrollmentInfo":539,"targetDuration":4,"studyType":57,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":546,"leadSponsor":548,"locationsCount":46},"100609833","temporal-interference-for-thalamocortical-activity-and-network-modulation-100609833","NCT07219719","Temporal Interference for Thalamocortical Activity and Network Modulation","TITAN","Inclusion Criteria:\n\n* Adults aged 18-50\n* Medically healthy\n* U.S. citizen or holding permanent resident status\n* English-speaking\n\nExclusion Criteria:\n\n* Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified in first MRI)\n* History of inpatient psychiatric hospitalization\n* History of head trauma resulting in prolonged loss of consciousness; or a history of greater than 3 grade I concussions\n* Current history of poorly controlled headaches including intractable or poorly controlled migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Possible pregnancy or plan to become pregnant in the next 6 months (self reported)\n* Any metal in the head\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)\n* Dental implants\n* Permanent retainers\n* Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions\n* Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions\n* Any medication that may alter seizure threshold taken during the study i.e., Attention-deficit\u002Fhyperactivity disorder (ADHD) stimulants (Adderall, amphetamine); Tricyclic\u002Fatypical antidepressants (amitriptyline, doxepin, imipramine, maprotiline, nortriptyline, bupropion); SSRIs (Escitalopram, Fluoxetine, Sertraline); Antipsychotics (chlorpromazine, clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antivirals (valacyclovir, ritonavir); over the counter antihistamines (diphenhydramine, Benadryl); Estradiol-based birth control\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for up to two hours\n* Regular night-shift work (second or third shift)\n* Sleep apnea or other sleep disorder (self-reported)",{"count":540,"type":23},40,[59],"The goal of this clinical trial is to find out whether a type of electrical brain stimulation, called temporal interference stimulation, can temporarily change the way different parts of the brain communicate with each other.\n\nParticipants will:\n\n* Complete two stimulation phases - overnight and during wakefulness\n* Undergo two MRIs per study phase",[500],{"date":352,"type":38},{"date":403,"type":38},{"date":547,"type":23},"2027-11",{"name":44,"class":45},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":54,"minAge":556,"maxAge":557,"enrollmentInfo":558,"targetDuration":4,"studyType":57,"phases":560,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":46},"100604825","comparing-outcomes-and-complications-following-mastisol-application-for-clubfoot-casting-100604825","NCT07154550","Comparing Outcomes and Complications Following Mastisol Application for Clubfoot Casting","A Randomized Controlled Trial Comparing Outcomes and Complications Following Mastisol Application for Clubfoot Casting","Inclusion Criteria:\n\n* Patients with bilateral clubfeet\n* Starting standard of care treatment with the Ponseti method between 0-12 weeks of age\n\n  * For patients born pre-maturely their eligibility age will be based on a corrected gestational age\n* Patients for whom at least one parent\u002Fguardian is able to converse, read, and write in English\n\nExclusion Criteria:\n\n* Patients who do not have bilateral clubfoot\n* Patients who are starting treatment for clubfoot after 12 weeks of age\n* Patients whose parents\u002Fguardians are unable to converse, read, and write in English\n* Patients whose parents\u002Fguardian do not provide or are not able to provide informed consent","0 Weeks","12 Weeks",{"count":559,"type":23},100,[81],"The purpose of this study is to assess if the application of Mastisol, a liquid adhesive, improves outcomes during bilateral clubfoot casting and reduces complications and development of complex clubfoot for the duration of their casting and up to 5 years follow-up.",[563],"Club Foot",{"date":352,"type":38},{"date":566,"type":38},"2026-02-11",{"date":568,"type":23},"2032-11",{"name":44,"class":45},""]